Get the Stockscreener App
1.41
5.37%
-0.08
After Hours:
1.41
Inmune Bio Inc stock is traded at $1.41, with a volume of 326.08K.
It is down -5.37% in the last 24 hours and down -2.76% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.49
Open:
$1.47
24h Volume:
326.08K
Relative Volume:
0.70
Market Cap:
$37.49M
Revenue:
$50,000
Net Income/Loss:
$-45.93M
P/E Ratio:
-0.7328
EPS:
-1.9241
Net Cash Flow:
$-23.62M
1W Performance:
+1.44%
1M Performance:
-2.76%
6M Performance:
-6.62%
1Y Performance:
-81.85%
1-Day Range:
$1.40
$1.495
1-Week Range:
$1.355
$1.79
52-Week Range:
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.41 | 39.61M | 50,000 | -45.93M | -23.62M | -1.9241 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform - marketscreener.com
Inmune Bio stock (US45764T1060): Year-end 2025 results and update in focus - AD HOC NEWS
INmune Bio publishes Alzheimer’s trial results in journal - Investing.com UK
INMB Shows Promising Alzheimer's Results in MINDFuL Trial - GuruFocus
INmune Bio: Interview With Co-Founder & CEO David Moss About The Immunotherapies Company - Pulse 2.0
INmune Bio publishes Alzheimer’s trial results in journal By Investing.com - Investing.com South Africa
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - The Manila Times
Alzheimer’s drug XPro shows directionally consistent benefits, no ARIA - Stock Titan
INmune Bio Receives FDA Fast Track for XPro - TipRanks
INMB Secures Fast Track Designation for Alzheimer's Treatment - GuruFocus
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
INmune Bio (INMB) Stock: Up +14.73%, Key Resistance at $1.76 2026-05-14Expert Entry Points - newser.com
INmune Bio's XPro1595 gets FDA Fast Track for early Alzheimer's treatment - Pluang
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug By Investing.com - Investing.com South Africa
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug - Investing.com
INmune Bio receives FDA fast track designation for XPro1595 in early Alzheimer's disease - marketscreener.com
INmune Bio receives FDA fast track status for Alzheimer’s drug - Investing.com
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - The Manila Times
INmune Bio receives FDA fast track status for Alzheimer’s drug By Investing.com - Investing.com UK
FDA Fast Tracks brain-inflammation drug for early Alzheimer’s - Stock Titan
INmune Bio (INMB) Q1 2026 Earnings Transcript - AOL.com
TradingKey - TradingKey
INmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call Transcript - Insider Monkey
INMB: INmune BioInteractive Chart - Zacks Investment Research
Expanding partnership aims to advance stem cell therapy to treat RDEB - Epidermolysis Bullosa News
Q1 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
INmune Bio, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
INMUNE BIO ($INMB) Releases Q1 2026 Earnings - Moomoo
Transcript : INmune Bio Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - The Manila Times
Earnings call transcript: INmune Bio Q1 2026 shows EPS beat, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: INmune Bio Q1 2026 shows EPS beat, stock dips - Investing.com
INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum - ChartMill
INmune Bio (NASDAQ: INMB) posts Q1 loss and flags going concern risks - Stock Titan
Alzheimer's drug moves toward Phase 2b/3 as CORDStrom nears UK filing - Stock Titan
Press Release: INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - Moomoo
INmune Bio Q1 2026 Earnings Call Transcript - MarketBeat
MSN Money - MSN
INmune Bio expands collaboration with Anthony Nolan charity By Investing.com - Investing.com Australia
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases - The Manila Times
INmune Bio expands collaboration with Anthony Nolan charity - Investing.com UK
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - 富途牛牛
INmune Bio Expands Cord Tissue License for CORDStrom Platform - TipRanks
Inmune Bio And Anthony Nolan Announce Strategic Expansion - TradingView
INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan
Stem cell supply deal broadens CORDStrom push into rare skin disease, cancer - Stock Titan
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):